We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Safety and Effectiveness Study of the MD-12-001 Stent in the Treatment of Superficial Femoral Artery or Popliteal Artery Blockages in Japanese Patients (Reliable)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01746550
Recruitment Status : Active, not recruiting
First Posted : December 11, 2012
Last Update Posted : March 24, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to assess the safety and effectiveness of the MD-12-001 stent in the treatment of superficial femoral artery and proximal popliteal artery blockages in Japanese patients.

Condition or disease Intervention/treatment
Arterial Occlusive Disease Device: MD-12-001 Stent

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm Clinical Trial in Japan for Reconstruction of Obstructive Lesions of the Superficial Femoral Artery or Proximal Popliteal Artery by Bard LifeStent.
Study Start Date : December 2012
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018
Arms and Interventions

Arm Intervention/treatment
Experimental: MD-12-001 Stent Arm
This study includes a single arm, the MD-12-001 Stent Arm.
Device: MD-12-001 Stent
MD-12-001 is a self-expanding nitinol stent
Other Name: Bard Lifestent Vascular Stent

Outcome Measures

Primary Outcome Measures :
  1. The proportion of subjects who are free of target limb failure at 12-months post study procedure. [ Time Frame: 12-months post study procedure ]

Secondary Outcome Measures :
  1. The proportion of subjects who are free of target limb failure. [ Time Frame: 30-days, 6-, 24-, and 36-months post study procedure ]
  2. The proportion of subjects with primary target lesion patency. [ Time Frame: 30-days, 6-, 12-, 24-, and 36-months post study procedure ]
    This endpoint will assess whether the study blockage has been unblocked using ultrasound imaging assessments reviewed by an independent core laboratory.

  3. The proportion of subjects with secondary target vessel/lesion patency. [ Time Frame: 30-days, 6-, 12-, 24-, and 36-months post study procedure ]
    This endpoint will assess whether the study blockage has shut again; where the target vessel/lesion no longer has blood flow or where surgical bypass of the vessel is performed.

  4. Proportion of subjects who achieve acute procedural success. [ Time Frame: Perioperative period (period during study procedure) ]
  5. Rutherford category assessment. [ Time Frame: Baseline, 30-days. 3-. 6-. 12-. 24-. 36-. 48- and 60-months post study procedure ]
    The assessment of peripheral artery disease severity will be performed using the Rutherford Classification system.

  6. Ankle-brachial index measurements. [ Time Frame: Baseline, 30-days, 3-, 6-, 12-, 24-, 36-, 48-, and 60-months post study procedure ]
    The ratio of blood pressure in the lower legs to the blood pressure in the arms will be calculated and assessed as a measure of disease severity.

  7. Quality of Life (SF-36) Questionnaire [ Time Frame: Baseline, 30-days, 3- , 6-, 12-, 24-, 36-, 48-, and 60-months post study procedure ]
    The SF-36 Quality of Life Questionnaire (QOL) will be used to evaluate QOL changes during study participation.

  8. Proportion of Subjects who experience Major Adverse Events. [ Time Frame: 30-days post procedure ]
    Major Adverse Events is defined as any death, stroke, myocardial infarction (heart attack) or target limb amputation.

  9. Proportions of Subjects who experience 1) any adverse event and 2) any serious adverse event. [ Time Frame: through 60-months post study procedure ]
  10. The proportion of subjects who undergo target vessel/lesion revascularization (restoration of blood flow) [ Time Frame: 12-, 24-, 36-, 48-, and 60-months post study procedure ]
  11. Proportion of subjects without stent fracture [ Time Frame: 30-days, 6-, 12-, 24, and 36-months post study procedure ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Rutherford Category 2-4 (mild intermittent claudication (pain while walking)to ischemic pain (pain due to decreased blood flow) at rest).
  • The target lesion(s) has evidence of narrowing or blockage and can be stented.
  • The total length of the lesion or series of lesions is estimated to be less than or equal to 150 mm.
  • The target vessel reference diameter is greater than or equal to 4.0 mm and less than or equal to 6.5 mm

Key Exclusion Criteria:

  • The subject has a known reaction (including allergic reaction) or sensitivity to blood thinning medications, or study device materials (nickel, titanium or tantalum)
  • The subject has a known sensitivity to medical imaging substances (contract media) that cannot be pretreated with medications (steroids or/and antihistamines)
  • The subject has a history of bleeding disorders (diatheses or coagulopathy).
  • The subject has kidney failure or is having dialysis treatment.
  • The subject has insufficient liver function, swelling of vein(s) caused by blood clot (thrombophlebitis), uremia, systemic lupus, or deep vein blood clots.
  • Subject has Acute Limb Ischemia (a sudden loss of blood flow to the limb).
  • Subject has a history of bypass surgery on the study vessel.
  • Subject has a history of heart attack or stroke within 6 months of study procedure.
  • The subject is receiving immunosuppressive therapy (medications that lower the body's normal immune response).
  • The subject is diagnosed with a severe infection (septicemia).
  • Principal investigator determines the subject's condition would prevent the subject from undergoing the study procedure or cannot support a vascular bypass graft.
  • The subject with a stent previously implanted into the target vessel.
  • Subject has disease in both legs where both limbs meet the inclusion criteria and it is planned to treat both limbs within 30 days.
  • Pregnant, possibly pregnant and/or nursing female subjects are excluded, as are female subjects who are willing to have a baby during the trial.
  • The subject is participating in an investigational drug or another investigational device study.
  • Subject has a large amount of blood clot next to the study lesion.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01746550

Kokura Kinen
Kitakyusyu, Fukuoka, Japan
Tokeidai Hospital
Sapporo, Hokkaido, Japan
Kansai Rosai Hospital
Amagasaki, Hyogo, Japan
Shonankamakura General Hospital
Kamakura, Kanagawa, Japan
Saiseikai Yokohamashi Tobu Hospital
Yokohama, Kanagawa, Japan
Sendai Kousei Hospital
Sendai, Miyagi, Japan
Nara Medical University Hospital
Kashihara, Nara, Japan
Kishiwada Tokushukai Hospital
Kishiwada, Osaka, Japan
Kasukabe Chuo General Hospital
Kasukabe, Saitama, Japan
Toho University Ohashi Hospital
Meguro, Tokyo, Japan
The Jikei University Hospital
Minato, Tokyo, Japan
Kyushu University Hospital
Fukuoka, Japan
Sponsors and Collaborators
C. R. Bard
Medicon, Inc.
Principal Investigator: Masato Nakamura Toho University Ohashi Hospital
More Information

Responsible Party: C. R. Bard
ClinicalTrials.gov Identifier: NCT01746550     History of Changes
Other Study ID Numbers: MED-12-001
First Posted: December 11, 2012    Key Record Dates
Last Update Posted: March 24, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases